OVOL2 impairs RHO GTPase signaling to restrain mitosis and aggressiveness of Anaplastic Thyroid Cancer

Background Anaplastic Thyroid Cancer (ATC) is an undifferentiated and aggressive tumor that often originates from well-Differentiated Thyroid Carcinoma (DTC) through a trans-differentiation process. Epithelial-to-Mesenchymal Transition (EMT) is recognized as one of the major players of this process....

Full description

Saved in:
Bibliographic Details
Published inJournal of experimental & clinical cancer research Vol. 41; no. 1; pp. 108 - 17
Main Authors Gugnoni, Mila, Manzotti, Gloria, Vitale, Emanuele, Sauta, Elisabetta, Torricelli, Federica, Reggiani, Francesca, Pistoni, Mariaelena, Piana, Simonetta, Ciarrocchi, Alessia
Format Journal Article
LanguageEnglish
Published London BioMed Central 25.03.2022
BioMed Central Ltd
BMC
Subjects
Analysis
Anaplastic thyroid cancer
Antibodies
Apoptosis
Biomedical and Life Sciences
Biomedicine
Cancer Research
Cell cycle
Cell death
Cell division
Chromatin
Cytoskeleton dynamics
Embryonic development
Epithelial-Mesenchymal Transition - genetics
Epithelial-to-Mesenchymal Transition
Experiments
Female
Flow cytometry
Gene expression
Genes
Growth factors
Humans
Immunology
Mitosis
Motility
Oncology
OVOL2
Pharmaceutical industry
Plasmids
Pregnancy
Prognosis
rho GTP-Binding Proteins - genetics
RNA
Scientific equipment and supplies industry
Stem cells
Thyroid cancer
Thyroid Carcinoma, Anaplastic - genetics
Thyroid Neoplasms - genetics
Thyroid Neoplasms - pathology
Transcription Factors - genetics
Wound healing
California
United States
Massachusetts
Germany
United States > US
Epithelial-to-Mesenchymal Transition
Anaplastic thyroid cancer
Mitosis
Cytoskeleton dynamics
OVOL2
Online AccessGet full text
ISSN1756-9966
0392-9078
1756-9966
DOI10.1186/s13046-022-02316-2

Cover

Abstract Background Anaplastic Thyroid Cancer (ATC) is an undifferentiated and aggressive tumor that often originates from well-Differentiated Thyroid Carcinoma (DTC) through a trans-differentiation process. Epithelial-to-Mesenchymal Transition (EMT) is recognized as one of the major players of this process. OVOL2 is a transcription factor (TF) that promotes epithelial differentiation and restrains EMT during embryonic development. OVOL2 loss in some types of cancers is linked to aggressiveness and poor prognosis. Here, we aim to clarify the unexplored role of OVOL2 in ATC. Methods Gene expression analysis in thyroid cancer patients and cell lines showed that OVOL2 is mainly associated with epithelial features and its expression is deeply impaired in ATC. To assess OVOL2 function, we established an OVOL2-overexpression model in ATC cell lines and evaluated its effects by analyzing gene expression, proliferation, invasion and migration abilities, cell cycle, specific protein localization through immunofluorescence staining. RNA-seq profiling showed that OVOL2 controls a complex network of genes converging on cell cycle and mitosis regulation and Chromatin Immunoprecipitation identified new OVOL2 target genes. Results Coherently with its reported function, OVOL2 re-expression restrained EMT and aggressiveness in ATC cells. Unexpectedly, we observed that it caused G2/M block, a consequent reduction in cell proliferation and an increase in cell death. This phenotype was associated to generalized abnormalities in the mitotic spindle structure and cytoskeletal organization. By RNA-seq experiments, we showed that many pathways related to cytoskeleton and migration, cell cycle and mitosis are profoundly affected by OVOL2 expression, in particular the RHO-GTPase pathway resulted as the most interesting. We demonstrated that RHO GTPase pathway is the central hub of OVOL2-mediated program in ATC and that OVOL2 transcriptionally inhibits RhoU and RhoJ. Silencing of RhoU recapitulated the OVOL2-driven phenotype pointing to this protein as a crucial target of OVOL2 in ATC. Conclusions Collectively, these data describe the role of OVOL2 in ATC and uncover a novel function of this TF in inhibiting the RHO GTPase pathway interlacing its effects on EMT, cytoskeleton dynamics and mitosis.
AbstractList Background Anaplastic Thyroid Cancer (ATC) is an undifferentiated and aggressive tumor that often originates from well-Differentiated Thyroid Carcinoma (DTC) through a trans-differentiation process. Epithelial-to-Mesenchymal Transition (EMT) is recognized as one of the major players of this process. OVOL2 is a transcription factor (TF) that promotes epithelial differentiation and restrains EMT during embryonic development. OVOL2 loss in some types of cancers is linked to aggressiveness and poor prognosis. Here, we aim to clarify the unexplored role of OVOL2 in ATC. Methods Gene expression analysis in thyroid cancer patients and cell lines showed that OVOL2 is mainly associated with epithelial features and its expression is deeply impaired in ATC. To assess OVOL2 function, we established an OVOL2-overexpression model in ATC cell lines and evaluated its effects by analyzing gene expression, proliferation, invasion and migration abilities, cell cycle, specific protein localization through immunofluorescence staining. RNA-seq profiling showed that OVOL2 controls a complex network of genes converging on cell cycle and mitosis regulation and Chromatin Immunoprecipitation identified new OVOL2 target genes. Results Coherently with its reported function, OVOL2 re-expression restrained EMT and aggressiveness in ATC cells. Unexpectedly, we observed that it caused G2/M block, a consequent reduction in cell proliferation and an increase in cell death. This phenotype was associated to generalized abnormalities in the mitotic spindle structure and cytoskeletal organization. By RNA-seq experiments, we showed that many pathways related to cytoskeleton and migration, cell cycle and mitosis are profoundly affected by OVOL2 expression, in particular the RHO-GTPase pathway resulted as the most interesting. We demonstrated that RHO GTPase pathway is the central hub of OVOL2-mediated program in ATC and that OVOL2 transcriptionally inhibits RhoU and RhoJ. Silencing of RhoU recapitulated the OVOL2-driven phenotype pointing to this protein as a crucial target of OVOL2 in ATC. Conclusions Collectively, these data describe the role of OVOL2 in ATC and uncover a novel function of this TF in inhibiting the RHO GTPase pathway interlacing its effects on EMT, cytoskeleton dynamics and mitosis. Keywords: Anaplastic thyroid cancer, OVOL2, Epithelial-to-Mesenchymal Transition, Mitosis, Cytoskeleton dynamics
Anaplastic Thyroid Cancer (ATC) is an undifferentiated and aggressive tumor that often originates from well-Differentiated Thyroid Carcinoma (DTC) through a trans-differentiation process. Epithelial-to-Mesenchymal Transition (EMT) is recognized as one of the major players of this process. OVOL2 is a transcription factor (TF) that promotes epithelial differentiation and restrains EMT during embryonic development. OVOL2 loss in some types of cancers is linked to aggressiveness and poor prognosis. Here, we aim to clarify the unexplored role of OVOL2 in ATC. Gene expression analysis in thyroid cancer patients and cell lines showed that OVOL2 is mainly associated with epithelial features and its expression is deeply impaired in ATC. To assess OVOL2 function, we established an OVOL2-overexpression model in ATC cell lines and evaluated its effects by analyzing gene expression, proliferation, invasion and migration abilities, cell cycle, specific protein localization through immunofluorescence staining. RNA-seq profiling showed that OVOL2 controls a complex network of genes converging on cell cycle and mitosis regulation and Chromatin Immunoprecipitation identified new OVOL2 target genes. Coherently with its reported function, OVOL2 re-expression restrained EMT and aggressiveness in ATC cells. Unexpectedly, we observed that it caused G2/M block, a consequent reduction in cell proliferation and an increase in cell death. This phenotype was associated to generalized abnormalities in the mitotic spindle structure and cytoskeletal organization. By RNA-seq experiments, we showed that many pathways related to cytoskeleton and migration, cell cycle and mitosis are profoundly affected by OVOL2 expression, in particular the RHO-GTPase pathway resulted as the most interesting. We demonstrated that RHO GTPase pathway is the central hub of OVOL2-mediated program in ATC and that OVOL2 transcriptionally inhibits RhoU and RhoJ. Silencing of RhoU recapitulated the OVOL2-driven phenotype pointing to this protein as a crucial target of OVOL2 in ATC. Collectively, these data describe the role of OVOL2 in ATC and uncover a novel function of this TF in inhibiting the RHO GTPase pathway interlacing its effects on EMT, cytoskeleton dynamics and mitosis.
Background Anaplastic Thyroid Cancer (ATC) is an undifferentiated and aggressive tumor that often originates from well-Differentiated Thyroid Carcinoma (DTC) through a trans-differentiation process. Epithelial-to-Mesenchymal Transition (EMT) is recognized as one of the major players of this process. OVOL2 is a transcription factor (TF) that promotes epithelial differentiation and restrains EMT during embryonic development. OVOL2 loss in some types of cancers is linked to aggressiveness and poor prognosis. Here, we aim to clarify the unexplored role of OVOL2 in ATC. Methods Gene expression analysis in thyroid cancer patients and cell lines showed that OVOL2 is mainly associated with epithelial features and its expression is deeply impaired in ATC. To assess OVOL2 function, we established an OVOL2-overexpression model in ATC cell lines and evaluated its effects by analyzing gene expression, proliferation, invasion and migration abilities, cell cycle, specific protein localization through immunofluorescence staining. RNA-seq profiling showed that OVOL2 controls a complex network of genes converging on cell cycle and mitosis regulation and Chromatin Immunoprecipitation identified new OVOL2 target genes. Results Coherently with its reported function, OVOL2 re-expression restrained EMT and aggressiveness in ATC cells. Unexpectedly, we observed that it caused G2/M block, a consequent reduction in cell proliferation and an increase in cell death. This phenotype was associated to generalized abnormalities in the mitotic spindle structure and cytoskeletal organization. By RNA-seq experiments, we showed that many pathways related to cytoskeleton and migration, cell cycle and mitosis are profoundly affected by OVOL2 expression, in particular the RHO-GTPase pathway resulted as the most interesting. We demonstrated that RHO GTPase pathway is the central hub of OVOL2-mediated program in ATC and that OVOL2 transcriptionally inhibits RhoU and RhoJ. Silencing of RhoU recapitulated the OVOL2-driven phenotype pointing to this protein as a crucial target of OVOL2 in ATC. Conclusions Collectively, these data describe the role of OVOL2 in ATC and uncover a novel function of this TF in inhibiting the RHO GTPase pathway interlacing its effects on EMT, cytoskeleton dynamics and mitosis.
Anaplastic Thyroid Cancer (ATC) is an undifferentiated and aggressive tumor that often originates from well-Differentiated Thyroid Carcinoma (DTC) through a trans-differentiation process. Epithelial-to-Mesenchymal Transition (EMT) is recognized as one of the major players of this process. OVOL2 is a transcription factor (TF) that promotes epithelial differentiation and restrains EMT during embryonic development. OVOL2 loss in some types of cancers is linked to aggressiveness and poor prognosis. Here, we aim to clarify the unexplored role of OVOL2 in ATC. Gene expression analysis in thyroid cancer patients and cell lines showed that OVOL2 is mainly associated with epithelial features and its expression is deeply impaired in ATC. To assess OVOL2 function, we established an OVOL2-overexpression model in ATC cell lines and evaluated its effects by analyzing gene expression, proliferation, invasion and migration abilities, cell cycle, specific protein localization through immunofluorescence staining. RNA-seq profiling showed that OVOL2 controls a complex network of genes converging on cell cycle and mitosis regulation and Chromatin Immunoprecipitation identified new OVOL2 target genes. Coherently with its reported function, OVOL2 re-expression restrained EMT and aggressiveness in ATC cells. Unexpectedly, we observed that it caused G2/M block, a consequent reduction in cell proliferation and an increase in cell death. This phenotype was associated to generalized abnormalities in the mitotic spindle structure and cytoskeletal organization. By RNA-seq experiments, we showed that many pathways related to cytoskeleton and migration, cell cycle and mitosis are profoundly affected by OVOL2 expression, in particular the RHO-GTPase pathway resulted as the most interesting. We demonstrated that RHO GTPase pathway is the central hub of OVOL2-mediated program in ATC and that OVOL2 transcriptionally inhibits RhoU and RhoJ. Silencing of RhoU recapitulated the OVOL2-driven phenotype pointing to this protein as a crucial target of OVOL2 in ATC. Collectively, these data describe the role of OVOL2 in ATC and uncover a novel function of this TF in inhibiting the RHO GTPase pathway interlacing its effects on EMT, cytoskeleton dynamics and mitosis.
Anaplastic Thyroid Cancer (ATC) is an undifferentiated and aggressive tumor that often originates from well-Differentiated Thyroid Carcinoma (DTC) through a trans-differentiation process. Epithelial-to-Mesenchymal Transition (EMT) is recognized as one of the major players of this process. OVOL2 is a transcription factor (TF) that promotes epithelial differentiation and restrains EMT during embryonic development. OVOL2 loss in some types of cancers is linked to aggressiveness and poor prognosis. Here, we aim to clarify the unexplored role of OVOL2 in ATC.BACKGROUNDAnaplastic Thyroid Cancer (ATC) is an undifferentiated and aggressive tumor that often originates from well-Differentiated Thyroid Carcinoma (DTC) through a trans-differentiation process. Epithelial-to-Mesenchymal Transition (EMT) is recognized as one of the major players of this process. OVOL2 is a transcription factor (TF) that promotes epithelial differentiation and restrains EMT during embryonic development. OVOL2 loss in some types of cancers is linked to aggressiveness and poor prognosis. Here, we aim to clarify the unexplored role of OVOL2 in ATC.Gene expression analysis in thyroid cancer patients and cell lines showed that OVOL2 is mainly associated with epithelial features and its expression is deeply impaired in ATC. To assess OVOL2 function, we established an OVOL2-overexpression model in ATC cell lines and evaluated its effects by analyzing gene expression, proliferation, invasion and migration abilities, cell cycle, specific protein localization through immunofluorescence staining. RNA-seq profiling showed that OVOL2 controls a complex network of genes converging on cell cycle and mitosis regulation and Chromatin Immunoprecipitation identified new OVOL2 target genes.METHODSGene expression analysis in thyroid cancer patients and cell lines showed that OVOL2 is mainly associated with epithelial features and its expression is deeply impaired in ATC. To assess OVOL2 function, we established an OVOL2-overexpression model in ATC cell lines and evaluated its effects by analyzing gene expression, proliferation, invasion and migration abilities, cell cycle, specific protein localization through immunofluorescence staining. RNA-seq profiling showed that OVOL2 controls a complex network of genes converging on cell cycle and mitosis regulation and Chromatin Immunoprecipitation identified new OVOL2 target genes.Coherently with its reported function, OVOL2 re-expression restrained EMT and aggressiveness in ATC cells. Unexpectedly, we observed that it caused G2/M block, a consequent reduction in cell proliferation and an increase in cell death. This phenotype was associated to generalized abnormalities in the mitotic spindle structure and cytoskeletal organization. By RNA-seq experiments, we showed that many pathways related to cytoskeleton and migration, cell cycle and mitosis are profoundly affected by OVOL2 expression, in particular the RHO-GTPase pathway resulted as the most interesting. We demonstrated that RHO GTPase pathway is the central hub of OVOL2-mediated program in ATC and that OVOL2 transcriptionally inhibits RhoU and RhoJ. Silencing of RhoU recapitulated the OVOL2-driven phenotype pointing to this protein as a crucial target of OVOL2 in ATC.RESULTSCoherently with its reported function, OVOL2 re-expression restrained EMT and aggressiveness in ATC cells. Unexpectedly, we observed that it caused G2/M block, a consequent reduction in cell proliferation and an increase in cell death. This phenotype was associated to generalized abnormalities in the mitotic spindle structure and cytoskeletal organization. By RNA-seq experiments, we showed that many pathways related to cytoskeleton and migration, cell cycle and mitosis are profoundly affected by OVOL2 expression, in particular the RHO-GTPase pathway resulted as the most interesting. We demonstrated that RHO GTPase pathway is the central hub of OVOL2-mediated program in ATC and that OVOL2 transcriptionally inhibits RhoU and RhoJ. Silencing of RhoU recapitulated the OVOL2-driven phenotype pointing to this protein as a crucial target of OVOL2 in ATC.Collectively, these data describe the role of OVOL2 in ATC and uncover a novel function of this TF in inhibiting the RHO GTPase pathway interlacing its effects on EMT, cytoskeleton dynamics and mitosis.CONCLUSIONSCollectively, these data describe the role of OVOL2 in ATC and uncover a novel function of this TF in inhibiting the RHO GTPase pathway interlacing its effects on EMT, cytoskeleton dynamics and mitosis.
Background Anaplastic Thyroid Cancer (ATC) is an undifferentiated and aggressive tumor that often originates from well-Differentiated Thyroid Carcinoma (DTC) through a trans-differentiation process. Epithelial-to-Mesenchymal Transition (EMT) is recognized as one of the major players of this process. OVOL2 is a transcription factor (TF) that promotes epithelial differentiation and restrains EMT during embryonic development. OVOL2 loss in some types of cancers is linked to aggressiveness and poor prognosis. Here, we aim to clarify the unexplored role of OVOL2 in ATC. Methods Gene expression analysis in thyroid cancer patients and cell lines showed that OVOL2 is mainly associated with epithelial features and its expression is deeply impaired in ATC. To assess OVOL2 function, we established an OVOL2-overexpression model in ATC cell lines and evaluated its effects by analyzing gene expression, proliferation, invasion and migration abilities, cell cycle, specific protein localization through immunofluorescence staining. RNA-seq profiling showed that OVOL2 controls a complex network of genes converging on cell cycle and mitosis regulation and Chromatin Immunoprecipitation identified new OVOL2 target genes. Results Coherently with its reported function, OVOL2 re-expression restrained EMT and aggressiveness in ATC cells. Unexpectedly, we observed that it caused G2/M block, a consequent reduction in cell proliferation and an increase in cell death. This phenotype was associated to generalized abnormalities in the mitotic spindle structure and cytoskeletal organization. By RNA-seq experiments, we showed that many pathways related to cytoskeleton and migration, cell cycle and mitosis are profoundly affected by OVOL2 expression, in particular the RHO-GTPase pathway resulted as the most interesting. We demonstrated that RHO GTPase pathway is the central hub of OVOL2-mediated program in ATC and that OVOL2 transcriptionally inhibits RhoU and RhoJ. Silencing of RhoU recapitulated the OVOL2-driven phenotype pointing to this protein as a crucial target of OVOL2 in ATC. Conclusions Collectively, these data describe the role of OVOL2 in ATC and uncover a novel function of this TF in inhibiting the RHO GTPase pathway interlacing its effects on EMT, cytoskeleton dynamics and mitosis.
Abstract Background Anaplastic Thyroid Cancer (ATC) is an undifferentiated and aggressive tumor that often originates from well-Differentiated Thyroid Carcinoma (DTC) through a trans-differentiation process. Epithelial-to-Mesenchymal Transition (EMT) is recognized as one of the major players of this process. OVOL2 is a transcription factor (TF) that promotes epithelial differentiation and restrains EMT during embryonic development. OVOL2 loss in some types of cancers is linked to aggressiveness and poor prognosis. Here, we aim to clarify the unexplored role of OVOL2 in ATC. Methods Gene expression analysis in thyroid cancer patients and cell lines showed that OVOL2 is mainly associated with epithelial features and its expression is deeply impaired in ATC. To assess OVOL2 function, we established an OVOL2-overexpression model in ATC cell lines and evaluated its effects by analyzing gene expression, proliferation, invasion and migration abilities, cell cycle, specific protein localization through immunofluorescence staining. RNA-seq profiling showed that OVOL2 controls a complex network of genes converging on cell cycle and mitosis regulation and Chromatin Immunoprecipitation identified new OVOL2 target genes. Results Coherently with its reported function, OVOL2 re-expression restrained EMT and aggressiveness in ATC cells. Unexpectedly, we observed that it caused G2/M block, a consequent reduction in cell proliferation and an increase in cell death. This phenotype was associated to generalized abnormalities in the mitotic spindle structure and cytoskeletal organization. By RNA-seq experiments, we showed that many pathways related to cytoskeleton and migration, cell cycle and mitosis are profoundly affected by OVOL2 expression, in particular the RHO-GTPase pathway resulted as the most interesting. We demonstrated that RHO GTPase pathway is the central hub of OVOL2-mediated program in ATC and that OVOL2 transcriptionally inhibits RhoU and RhoJ. Silencing of RhoU recapitulated the OVOL2-driven phenotype pointing to this protein as a crucial target of OVOL2 in ATC. Conclusions Collectively, these data describe the role of OVOL2 in ATC and uncover a novel function of this TF in inhibiting the RHO GTPase pathway interlacing its effects on EMT, cytoskeleton dynamics and mitosis.
ArticleNumber 108
Audience Academic
Author Piana, Simonetta
Manzotti, Gloria
Reggiani, Francesca
Sauta, Elisabetta
Pistoni, Mariaelena
Gugnoni, Mila
Ciarrocchi, Alessia
Vitale, Emanuele
Torricelli, Federica
Author_xml – sequence: 1
  givenname: Mila
  surname: Gugnoni
  fullname: Gugnoni, Mila
  organization: Laboratory of Translational Research, Azienda USL-IRCCS Di Reggio Emilia
– sequence: 2
  givenname: Gloria
  orcidid: 0000-0002-0639-3605
  surname: Manzotti
  fullname: Manzotti, Gloria
  email: gloria.manzotti@ausl.re.it, alessia.ciarrocchi@ausl.re.it
  organization: Laboratory of Translational Research, Azienda USL-IRCCS Di Reggio Emilia
– sequence: 3
  givenname: Emanuele
  surname: Vitale
  fullname: Vitale, Emanuele
  organization: Laboratory of Translational Research, Azienda USL-IRCCS Di Reggio Emilia, Clinical and Experimental Medicine PhD Program, University of Modena and Reggio Emilia
– sequence: 4
  givenname: Elisabetta
  surname: Sauta
  fullname: Sauta, Elisabetta
  organization: Department of Electrical, Computer and Biomedical Engineering, University of Pavia
– sequence: 5
  givenname: Federica
  surname: Torricelli
  fullname: Torricelli, Federica
  organization: Laboratory of Translational Research, Azienda USL-IRCCS Di Reggio Emilia
– sequence: 6
  givenname: Francesca
  surname: Reggiani
  fullname: Reggiani, Francesca
  organization: Laboratory of Translational Research, Azienda USL-IRCCS Di Reggio Emilia
– sequence: 7
  givenname: Mariaelena
  surname: Pistoni
  fullname: Pistoni, Mariaelena
  organization: Laboratory of Translational Research, Azienda USL-IRCCS Di Reggio Emilia
– sequence: 8
  givenname: Simonetta
  surname: Piana
  fullname: Piana, Simonetta
  organization: Pathology Unit, Department of Oncology and Advanced Technologies, Azienda USL-IRCCS Di Reggio Emilia
– sequence: 9
  givenname: Alessia
  surname: Ciarrocchi
  fullname: Ciarrocchi, Alessia
  email: gloria.manzotti@ausl.re.it, alessia.ciarrocchi@ausl.re.it
  organization: Laboratory of Translational Research, Azienda USL-IRCCS Di Reggio Emilia
BackLink https://www.ncbi.nlm.nih.gov/pubmed/35337349$$D View this record in MEDLINE/PubMed
BookMark eNp9kl1r2zAYhc3oWD-2P7CLIRiM3bjThyVLN4MQtrYQyBjZboUsyY6CLWWSU-i_n9y0a1JGMULm9XOOrMM5L0588LYo3iN4iRBnXxIisGIlxDgvgliJXxVnqKasFIKxk4P30-I8pQ2EDAkk3hSnhBJSk0qcFe3y93KBgRu2ysUEfl4vwdXqh0oWJNd51TvfgTGAaNMYlfNgcGNILgHlDVBdl-fJ3VqfNxBaMPNq26s0Og1W67sYnAFz5bWNb4vXreqTffewXxS_vn9bza_LxfLqZj5blJoRPpbGcmqVqQ1nnNcNbXFtaAONZUa3xmjMGq5J3QoDhaqU1Rg2iBomeA0hVi25KG72viaojdxGN6h4J4Ny8n4QYidVzL_XW8lpXXGDaYNJNVlx3lQKQqI4RE0lbPb6uvfa7prBGm19jqA_Mj3-4t1aduFWckFrJGg2-PxgEMOfXU5QDi5p2_fK27BLErOqghAJSDL68Rm6CbuY858oigTHlKMnqlP5As63IZ-rJ1M5yxmQ6VCWqcv_UPkxdnA6V6h1eX4k-HQgWFvVj-sU-t3ogk_H4IfDRP5F8VinDPA9oGNIKdpWajeqyWdqTy8RlFNz5b65MjdX3jdX4izFz6SP7i-KyF6UMuw7G59ie0H1FzaQ_l0
CitedBy_id crossref_primary_10_1016_j_tcb_2023_05_008
crossref_primary_10_1016_j_isci_2024_108873
crossref_primary_10_1038_s41598_025_88134_w
crossref_primary_10_1038_s41417_024_00792_6
crossref_primary_10_1007_s11033_023_09140_7
crossref_primary_10_1038_s41419_024_07058_x
crossref_primary_10_1016_j_canlet_2024_216950
crossref_primary_10_1007_s10495_023_01861_1
crossref_primary_10_1016_j_compbiolchem_2024_108311
crossref_primary_10_1038_s41467_024_46778_8
crossref_primary_10_3390_ijms25084224
crossref_primary_10_1096_fj_202400400RR
crossref_primary_10_3389_fphar_2023_1137151
Cites_doi 10.1158/1538-7445.AM2020-1525
10.1083/jcb.144.2.315
10.1038/s41388-019-0963-7
10.1007/s10585-007-9119-1
10.1016/j.devcel.2014.03.006
10.1242/jcs.175539
10.1158/0008-5472.CAN-04-2247
10.1359/jbmr.060613
10.1242/jcs.03456
10.1016/S0079-6107(98)00052-2
10.1074/jbc.M112.418376
10.1038/ncb1230
10.1101/gad.1310805
10.1093/nar/gkw377
10.1053/j.gastro.2015.11.041
10.1016/j.cub.2004.11.011
10.1038/s41598-019-43021-z
10.1182/blood-2010-10-315275
10.1093/bioinformatics/bts635
10.1016/j.ydbio.2005.12.003
10.1021/acs.jproteome.8b00702
10.1038/35099066
10.1083/jcb.200603069
10.2174/156800910791517154
10.1245/s10434-007-9562-x
10.1172/JCI39104
10.1158/1078-0432.CCR-18-2364
10.1002/bies.10262
10.1101/gad.894301
10.1038/nrc822
10.1097/01.LAB.0000073128.16098.31
10.1016/0022-1759(91)90198-O
10.1093/molbev/msl145
10.1007/s00428-020-02891-9
10.1016/j.bbrc.2004.01.108
10.1038/nmeth.3630
10.4161/cam.5.2.14403
10.1083/jcb.200508196
10.3389/fcell.2019.00127
10.1186/s13059-014-0550-8
10.1038/s41556-018-0226-9
10.1242/dev.063867
10.1073/pnas.1821905116
10.1074/jbc.M109.008847
10.1016/j.ejso.2006.05.012
10.1242/jcs.039446
10.1038/22330
10.1038/sj.onc.1203877
10.1038/s41388-018-0615-3
10.7150/thno.24003
10.1038/onc.2012.42
10.1128/MCB.00201-07
10.1038/s41556-018-0220-2
10.1038/ng.2359
10.1007/s10911-009-9110-3
10.1016/j.ydbio.2014.02.014
10.1016/j.gene.2016.11.034
10.1007/s12022-013-9272-9
10.1080/10409238.2020.1810622
10.1016/j.ceb.2005.08.012
10.1002/bies.20238
10.1038/33719
10.1038/nmeth.2089
10.1016/j.devcel.2020.04.016
10.1038/sj.onc.1209682
10.1016/j.ccr.2013.12.010
10.1073/pnas.0712044105
10.1038/nrc725
10.1128/MCB.00336-08
10.1038/modpathol.2016.169
10.1007/s12020-019-02030-8
10.1006/jsre.1998.5369
10.1016/j.bbamcr.2004.04.007
10.1038/s41419-021-03425-0
10.1016/j.devcel.2010.07.015
10.1091/mbc.8.1.109
10.1016/j.oraloncology.2013.03.440
10.1126/science.1246981
10.4161/trns.2.5.16904
10.1016/j.cell.2008.03.027
10.1097/00005537-200107000-00027
10.1042/BJ20090061
10.1371/journal.pone.0076773
10.1101/gr.1239303
10.1073/pnas.1307405110
ContentType Journal Article
Copyright The Author(s) 2022
2022. The Author(s).
COPYRIGHT 2022 BioMed Central Ltd.
2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: The Author(s) 2022
– notice: 2022. The Author(s).
– notice: COPYRIGHT 2022 BioMed Central Ltd.
– notice: 2022. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID C6C
AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
K9.
M0S
M1P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1186/s13046-022-02316-2
DatabaseName Springer Nature OA Free Journals
CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Central
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
ProQuest Health & Medical Collection
Proquest Medical Database
ProQuest Central Premium
ProQuest One Academic (New)
ProQuest Publicly Available Content
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Open Access Full Text
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Central China
ProQuest Central
Health Research Premium Collection
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
ProQuest Central (New)
ProQuest Medical Library (Alumni)
ProQuest One Academic Eastern Edition
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Health & Medical Complete
ProQuest Medical Library
ProQuest One Academic UKI Edition
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList
MEDLINE
Publicly Available Content Database

MEDLINE - Academic
Database_xml – sequence: 1
  dbid: C6C
  name: Springer Nature OA Free Journals
  url: http://www.springeropen.com/
  sourceTypes: Publisher
– sequence: 2
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 3
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 4
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 5
  dbid: BENPR
  name: ProQuest Central
  url: http://www.proquest.com/pqcentral?accountid=15518
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1756-9966
EndPage 17
ExternalDocumentID oai_doaj_org_article_85748d25b2344aec88b4a003a801b49e
PMC8957195
A698319536
35337349
10_1186_s13046_022_02316_2
Genre Journal Article
GeographicLocations California
United States
Massachusetts
Germany
United States--US
GeographicLocations_xml – name: California
– name: Germany
– name: United States
– name: Massachusetts
– name: United States--US
GrantInformation_xml – fundername: Fondazione Umberto Veronesi
  funderid: http://dx.doi.org/10.13039/501100004710
– fundername: Agenzia Italiana del Farmaco, Ministero della Salute
  grantid: RF-2016-02364167
  funderid: http://dx.doi.org/10.13039/501100003197
– fundername: Agenzia Italiana del Farmaco, Ministero della Salute
  grantid: RF-2016-02364167
– fundername: ;
– fundername: ;
  grantid: RF-2016-02364167
GroupedDBID ---
0R~
29K
2WC
4.4
5GY
5VS
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
AASML
ABDBF
ABUWG
ACGFO
ACGFS
ADBBV
ADRAZ
ADUKV
AENEX
AFKRA
AFPKN
AHBYD
AHMBA
AHYZX
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AOIJS
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C6C
CCPQU
CS3
D-I
DIK
DU5
E3Z
EBD
EBLON
EBS
ESX
F5P
FYUFA
GROUPED_DOAJ
HMCUK
HYE
IAO
IEA
IHR
IHW
INH
INR
ITC
KQ8
M1P
M48
M~E
O5R
O5S
OK1
OVT
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PJZUB
PPXIY
PQQKQ
PROAC
PSQYO
PUEGO
RBZ
RNS
ROL
RPM
RSV
SMD
SOJ
TR2
TUS
UKHRP
~8M
AAYXX
ALIPV
CITATION
-5E
-5G
-A0
-BR
3V.
ACRMQ
ADINQ
C24
CGR
CUY
CVF
ECM
EIF
NPM
PMFND
7XB
8FK
AZQEC
DWQXO
K9.
PKEHL
PQEST
PQUKI
PRINS
7X8
5PM
ID FETCH-LOGICAL-c638t-de85ead7d86887b5f27d5b0de6dcfddc26b8c37f9d09a4aec20b15d6987002af3
IEDL.DBID DOA
ISSN 1756-9966
0392-9078
IngestDate Wed Aug 27 00:58:02 EDT 2025
Thu Aug 21 18:32:04 EDT 2025
Thu Sep 04 21:20:18 EDT 2025
Sun Sep 07 03:32:21 EDT 2025
Tue Jun 17 21:10:14 EDT 2025
Tue Jun 10 20:52:48 EDT 2025
Thu May 22 21:22:43 EDT 2025
Thu Jan 02 22:54:30 EST 2025
Thu Apr 24 23:00:53 EDT 2025
Tue Jul 01 02:26:47 EDT 2025
Sat Sep 06 07:24:02 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Keywords Epithelial-to-Mesenchymal Transition
Anaplastic thyroid cancer
Mitosis
Cytoskeleton dynamics
OVOL2
Language English
License 2022. The Author(s).
Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c638t-de85ead7d86887b5f27d5b0de6dcfddc26b8c37f9d09a4aec20b15d6987002af3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0002-0639-3605
OpenAccessLink https://doaj.org/article/85748d25b2344aec88b4a003a801b49e
PMID 35337349
PQID 2651982581
PQPubID 105475
PageCount 17
ParticipantIDs doaj_primary_oai_doaj_org_article_85748d25b2344aec88b4a003a801b49e
pubmedcentral_primary_oai_pubmedcentral_nih_gov_8957195
proquest_miscellaneous_2644001903
proquest_journals_2651982581
gale_infotracmisc_A698319536
gale_infotracacademiconefile_A698319536
gale_healthsolutions_A698319536
pubmed_primary_35337349
crossref_citationtrail_10_1186_s13046_022_02316_2
crossref_primary_10_1186_s13046_022_02316_2
springer_journals_10_1186_s13046_022_02316_2
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2022-03-25
PublicationDateYYYYMMDD 2022-03-25
PublicationDate_xml – month: 03
  year: 2022
  text: 2022-03-25
  day: 25
PublicationDecade 2020
PublicationPlace London
PublicationPlace_xml – name: London
– name: England
PublicationTitle Journal of experimental & clinical cancer research
PublicationTitleAbbrev J Exp Clin Cancer Res
PublicationTitleAlternate J Exp Clin Cancer Res
PublicationYear 2022
Publisher BioMed Central
BioMed Central Ltd
BMC
Publisher_xml – name: BioMed Central
– name: BioMed Central Ltd
– name: BMC
References JP Thiery (2316_CR6) 2002; 2
NT Doncheva (2316_CR28) 2019; 18
EK Duperret (2316_CR86) 2015; 128
J Seong (2316_CR77) 2013; 110
YW Liu (2316_CR82) 1998; 77
F Payre (2316_CR11) 1999; 400
A Hakem (2316_CR54) 2005; 19
A Tameni (2316_CR65) 2021; 12
BG Hollier (2316_CR9) 2009; 14
M Nair (2316_CR10) 2006; 173
MI Love (2316_CR26) 2014; 15
PJ Bhavsar (2316_CR66) 2013; 32
DC Brady (2316_CR71) 2009; 29
MT Abraham (2316_CR48) 2001; 111
E Lozano (2316_CR57) 2003; 25
GH Ashton (2316_CR83) 2010; 19
Y Yamakita (2316_CR33) 1999; 144
DI Bellovin (2316_CR56) 2006; 25
JT Parsons (2316_CR80) 2000; 19
PI Thakore (2316_CR22) 2015; 12
ZH Wang (2316_CR16) 2017; 600
T Wang (2316_CR21) 2014; 343
H Roca (2316_CR14) 2013; 8
A Faried (2316_CR52) 2007; 14
C Montemayor-Garcia (2316_CR3) 2013; 24
M Ragazzi (2316_CR2) 2021; 478
M Krauthammer (2316_CR45) 2012; 44
R Zaidel-Bar (2316_CR32) 2018; 20
CW Jung (2316_CR4) 2015; 8
VM Braga (2316_CR58) 2005; 17
CG Reverte (2316_CR85) 2006; 174
H Shakib (2316_CR19) 2019; 66
KJ Simpson (2316_CR55) 2004; 64
K Watanabe (2316_CR37) 2019; 9
JY Ryu (2316_CR88) 2019; 116
DR Mackay (2316_CR35) 2006; 291
XK Qi (2316_CR15) 2018; 8
G Manzotti (2316_CR20) 2019; 25
R Kalluri (2316_CR30) 2009; 119
YY Chuang (2316_CR72) 2007; 120
W Tao (2316_CR62) 2001; 15
S Phuyal (2316_CR41) 2019; 7
L Yuan (2316_CR67) 2011; 118
M Dickover (2316_CR69) 2014; 389
SA Mani (2316_CR8) 2008; 133
RG Hodge (2316_CR43) 2020; 55
CA Schneider (2316_CR24) 2012; 9
JG Lock (2316_CR31) 2018; 20
2316_CR34
R Zhang (2316_CR39) 2019; 38
P Descargues (2316_CR13) 2008; 105
D Spiering (2316_CR42) 2011; 5
J Wells (2316_CR38) 2009; 284
S Huveneers (2316_CR75) 2009; 122
D Schiavone (2316_CR63) 2009; 421
MV Kuleshov (2316_CR27) 2016; 44
DA Loebel (2316_CR70) 2011; 138
SI Ellenbroek (2316_CR59) 2007; 24
MA Wozniak (2316_CR76) 2004; 1692
DD Schlaepfer (2316_CR81) 1999; 71
LP Cramer (2316_CR84) 1997; 8
JP O'Neill (2316_CR1) 2013; 49
T Gómez del Pulgar (2316_CR46) 2005; 27
A Boureux (2316_CR40) 2007; 24
C Raimondi (2316_CR7) 2010; 10
ME Chicurel (2316_CR78) 1998; 392
A Dobin (2316_CR25) 2013; 29
S Wilkinson (2316_CR53) 2005; 7
I Nicoletti (2316_CR23) 1991; 139
AA Arraf (2316_CR73) 2020; 53
E Wilson (2316_CR87) 2014; 127
A Horiuchi (2316_CR49) 2003; 83
P Shannon (2316_CR29) 2003; 13
XR Li (2316_CR47) 2006; 32
H Brazier (2316_CR64) 2006; 21
Y Pan (2316_CR51) 2004; 315
GD Ye (2316_CR18) 2016; 150
JH Svensmark (2316_CR44) 2019; 38
K Watanabe (2316_CR36) 2014; 29
T Zhang (2316_CR12) 2013; 288
E Sahai (2316_CR60) 2002; 2
DR Croft (2316_CR61) 2011; 2
T Kamai (2316_CR50) 2003; 9
A Shutes (2316_CR68) 2004; 14
B Geiger (2316_CR79) 2001; 2
RR Pharaon (2316_CR5) 2020; 80
T Ito (2316_CR17) 2017; 30
C Kim (2316_CR89) 2014; 25
A Ruusala (2316_CR74) 2008; 28
References_xml – volume: 80
  start-page: 1525
  issue: 16 Supplement
  year: 2020
  ident: 2316_CR5
  publication-title: Cancer Research
  doi: 10.1158/1538-7445.AM2020-1525
– volume: 144
  start-page: 315
  issue: 2
  year: 1999
  ident: 2316_CR33
  publication-title: J Cell Biol
  doi: 10.1083/jcb.144.2.315
– volume: 38
  start-page: 7447
  issue: 50
  year: 2019
  ident: 2316_CR44
  publication-title: Oncogene
  doi: 10.1038/s41388-019-0963-7
– volume: 24
  start-page: 657
  issue: 8
  year: 2007
  ident: 2316_CR59
  publication-title: Clin Exp Metastasis
  doi: 10.1007/s10585-007-9119-1
– volume: 29
  start-page: 59
  issue: 1
  year: 2014
  ident: 2316_CR36
  publication-title: Dev Cell
  doi: 10.1016/j.devcel.2014.03.006
– volume: 128
  start-page: 3997
  issue: 21
  year: 2015
  ident: 2316_CR86
  publication-title: J Cell Sci
  doi: 10.1242/jcs.175539
– volume: 9
  start-page: 2632
  issue: 7
  year: 2003
  ident: 2316_CR50
  publication-title: Clin Cancer Res
– volume: 64
  start-page: 8694
  issue: 23
  year: 2004
  ident: 2316_CR55
  publication-title: Cancer Res
  doi: 10.1158/0008-5472.CAN-04-2247
– volume: 21
  start-page: 1387
  issue: 9
  year: 2006
  ident: 2316_CR64
  publication-title: J Bone Miner Res
  doi: 10.1359/jbmr.060613
– volume: 120
  start-page: 1927
  issue: Pt 11
  year: 2007
  ident: 2316_CR72
  publication-title: J Cell Sci
  doi: 10.1242/jcs.03456
– volume: 71
  start-page: 435
  issue: 3–4
  year: 1999
  ident: 2316_CR81
  publication-title: Prog Biophys Mol Biol
  doi: 10.1016/S0079-6107(98)00052-2
– volume: 288
  start-page: 6166
  issue: 9
  year: 2013
  ident: 2316_CR12
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M112.418376
– volume: 7
  start-page: 255
  issue: 3
  year: 2005
  ident: 2316_CR53
  publication-title: Nat Cell Biol
  doi: 10.1038/ncb1230
– volume: 19
  start-page: 1974
  issue: 17
  year: 2005
  ident: 2316_CR54
  publication-title: Genes Dev
  doi: 10.1101/gad.1310805
– volume: 44
  start-page: W90
  issue: W1
  year: 2016
  ident: 2316_CR27
  publication-title: Nucleic Acids Res
  doi: 10.1093/nar/gkw377
– volume: 150
  start-page: 659
  issue: 3
  year: 2016
  ident: 2316_CR18
  publication-title: Gastroenterology
  doi: 10.1053/j.gastro.2015.11.041
– volume: 14
  start-page: 2052
  issue: 22
  year: 2004
  ident: 2316_CR68
  publication-title: Curr Biol
  doi: 10.1016/j.cub.2004.11.011
– volume: 9
  start-page: 6490
  issue: 1
  year: 2019
  ident: 2316_CR37
  publication-title: Sci Rep
  doi: 10.1038/s41598-019-43021-z
– volume: 118
  start-page: 1145
  issue: 4
  year: 2011
  ident: 2316_CR67
  publication-title: Blood
  doi: 10.1182/blood-2010-10-315275
– volume: 29
  start-page: 15
  issue: 1
  year: 2013
  ident: 2316_CR25
  publication-title: Bioinformatics
  doi: 10.1093/bioinformatics/bts635
– volume: 291
  start-page: 38
  issue: 1
  year: 2006
  ident: 2316_CR35
  publication-title: Dev Biol
  doi: 10.1016/j.ydbio.2005.12.003
– volume: 18
  start-page: 623
  issue: 2
  year: 2019
  ident: 2316_CR28
  publication-title: J Proteome Res
  doi: 10.1021/acs.jproteome.8b00702
– volume: 8
  start-page: 560
  issue: 1
  year: 2015
  ident: 2316_CR4
  publication-title: Int J Clin Exp Pathol
– volume: 2
  start-page: 793
  issue: 11
  year: 2001
  ident: 2316_CR79
  publication-title: Nat Rev Mol Cell Biol
  doi: 10.1038/35099066
– volume: 174
  start-page: 491
  issue: 4
  year: 2006
  ident: 2316_CR85
  publication-title: J Cell Biol
  doi: 10.1083/jcb.200603069
– ident: 2316_CR34
– volume: 10
  start-page: 496
  issue: 5
  year: 2010
  ident: 2316_CR7
  publication-title: Curr Cancer Drug Targets
  doi: 10.2174/156800910791517154
– volume: 14
  start-page: 3593
  issue: 12
  year: 2007
  ident: 2316_CR52
  publication-title: Ann Surg Oncol
  doi: 10.1245/s10434-007-9562-x
– volume: 119
  start-page: 1420
  issue: 6
  year: 2009
  ident: 2316_CR30
  publication-title: J Clin Invest
  doi: 10.1172/JCI39104
– volume: 25
  start-page: 2348
  issue: 7
  year: 2019
  ident: 2316_CR20
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-18-2364
– volume: 25
  start-page: 452
  issue: 5
  year: 2003
  ident: 2316_CR57
  publication-title: BioEssays
  doi: 10.1002/bies.10262
– volume: 15
  start-page: 1796
  issue: 14
  year: 2001
  ident: 2316_CR62
  publication-title: Genes Dev
  doi: 10.1101/gad.894301
– volume: 2
  start-page: 442
  issue: 6
  year: 2002
  ident: 2316_CR6
  publication-title: Nat Rev Cancer
  doi: 10.1038/nrc822
– volume: 83
  start-page: 861
  issue: 6
  year: 2003
  ident: 2316_CR49
  publication-title: Lab Invest
  doi: 10.1097/01.LAB.0000073128.16098.31
– volume: 139
  start-page: 271
  issue: 2
  year: 1991
  ident: 2316_CR23
  publication-title: J Immunol Methods
  doi: 10.1016/0022-1759(91)90198-O
– volume: 24
  start-page: 203
  issue: 1
  year: 2007
  ident: 2316_CR40
  publication-title: Mol Biol Evol
  doi: 10.1093/molbev/msl145
– volume: 478
  start-page: 265
  issue: 2
  year: 2021
  ident: 2316_CR2
  publication-title: Virchows Arch
  doi: 10.1007/s00428-020-02891-9
– volume: 315
  start-page: 686
  issue: 3
  year: 2004
  ident: 2316_CR51
  publication-title: Biochem Biophys Res Commun
  doi: 10.1016/j.bbrc.2004.01.108
– volume: 12
  start-page: 1143
  issue: 12
  year: 2015
  ident: 2316_CR22
  publication-title: Nat Methods
  doi: 10.1038/nmeth.3630
– volume: 5
  start-page: 170
  issue: 2
  year: 2011
  ident: 2316_CR42
  publication-title: Cell Adh Migr
  doi: 10.4161/cam.5.2.14403
– volume: 173
  start-page: 253
  issue: 2
  year: 2006
  ident: 2316_CR10
  publication-title: J Cell Biol
  doi: 10.1083/jcb.200508196
– volume: 7
  start-page: 127
  year: 2019
  ident: 2316_CR41
  publication-title: Front Cell Dev Biol
  doi: 10.3389/fcell.2019.00127
– volume: 15
  start-page: 550
  issue: 12
  year: 2014
  ident: 2316_CR26
  publication-title: Genome Biol
  doi: 10.1186/s13059-014-0550-8
– volume: 20
  start-page: 1233
  issue: 11
  year: 2018
  ident: 2316_CR32
  publication-title: Nat Cell Biol
  doi: 10.1038/s41556-018-0226-9
– volume: 138
  start-page: 4511
  issue: 20
  year: 2011
  ident: 2316_CR70
  publication-title: Development
  doi: 10.1242/dev.063867
– volume: 116
  start-page: 13996
  issue: 28
  year: 2019
  ident: 2316_CR88
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.1821905116
– volume: 284
  start-page: 29125
  issue: 42
  year: 2009
  ident: 2316_CR38
  publication-title: J Biol Chem
  doi: 10.1074/jbc.M109.008847
– volume: 32
  start-page: 1130
  issue: 10
  year: 2006
  ident: 2316_CR47
  publication-title: Eur J Surg Oncol
  doi: 10.1016/j.ejso.2006.05.012
– volume: 122
  start-page: 1059
  issue: Pt 8
  year: 2009
  ident: 2316_CR75
  publication-title: Src and Rho J Cell Sci
  doi: 10.1242/jcs.039446
– volume: 400
  start-page: 271
  issue: 6741
  year: 1999
  ident: 2316_CR11
  publication-title: Nature
  doi: 10.1038/22330
– volume: 19
  start-page: 5606
  issue: 49
  year: 2000
  ident: 2316_CR80
  publication-title: Oncogene
  doi: 10.1038/sj.onc.1203877
– volume: 38
  start-page: 2750
  issue: 15
  year: 2019
  ident: 2316_CR39
  publication-title: Oncogene
  doi: 10.1038/s41388-018-0615-3
– volume: 8
  start-page: 2202
  issue: 8
  year: 2018
  ident: 2316_CR15
  publication-title: Theranostics
  doi: 10.7150/thno.24003
– volume: 32
  start-page: 198
  issue: 2
  year: 2013
  ident: 2316_CR66
  publication-title: Oncogene
  doi: 10.1038/onc.2012.42
– volume: 28
  start-page: 1802
  issue: 5
  year: 2008
  ident: 2316_CR74
  publication-title: Mol Cell Biol
  doi: 10.1128/MCB.00201-07
– volume: 20
  start-page: 1290
  issue: 11
  year: 2018
  ident: 2316_CR31
  publication-title: Nat Cell Biol
  doi: 10.1038/s41556-018-0220-2
– volume: 44
  start-page: 1006
  issue: 9
  year: 2012
  ident: 2316_CR45
  publication-title: Nat Genet
  doi: 10.1038/ng.2359
– volume: 14
  start-page: 29
  issue: 1
  year: 2009
  ident: 2316_CR9
  publication-title: J Mammary Gland Biol Neoplasia
  doi: 10.1007/s10911-009-9110-3
– volume: 389
  start-page: 182
  issue: 2
  year: 2014
  ident: 2316_CR69
  publication-title: Dev Biol
  doi: 10.1016/j.ydbio.2014.02.014
– volume: 600
  start-page: 1
  year: 2017
  ident: 2316_CR16
  publication-title: Gene
  doi: 10.1016/j.gene.2016.11.034
– volume: 24
  start-page: 206
  issue: 4
  year: 2013
  ident: 2316_CR3
  publication-title: Endocr Pathol
  doi: 10.1007/s12022-013-9272-9
– volume: 55
  start-page: 386
  issue: 4
  year: 2020
  ident: 2316_CR43
  publication-title: Crit Rev Biochem Mol Biol
  doi: 10.1080/10409238.2020.1810622
– volume: 17
  start-page: 466
  issue: 5
  year: 2005
  ident: 2316_CR58
  publication-title: Curr Opin Cell Biol
  doi: 10.1016/j.ceb.2005.08.012
– volume: 27
  start-page: 602
  issue: 6
  year: 2005
  ident: 2316_CR46
  publication-title: Bioessays
  doi: 10.1002/bies.20238
– volume: 392
  start-page: 730
  issue: 6677
  year: 1998
  ident: 2316_CR78
  publication-title: Nature
  doi: 10.1038/33719
– volume: 9
  start-page: 671
  issue: 7
  year: 2012
  ident: 2316_CR24
  publication-title: Nat Methods
  doi: 10.1038/nmeth.2089
– volume: 53
  start-page: 589
  issue: 5
  year: 2020
  ident: 2316_CR73
  publication-title: Dev Cell
  doi: 10.1016/j.devcel.2020.04.016
– volume: 25
  start-page: 6959
  issue: 52
  year: 2006
  ident: 2316_CR56
  publication-title: Oncogene
  doi: 10.1038/sj.onc.1209682
– volume: 25
  start-page: 102
  issue: 1
  year: 2014
  ident: 2316_CR89
  publication-title: Cancer Cell
  doi: 10.1016/j.ccr.2013.12.010
– volume: 105
  start-page: 2487
  issue: 7
  year: 2008
  ident: 2316_CR13
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.0712044105
– volume: 2
  start-page: 133
  issue: 2
  year: 2002
  ident: 2316_CR60
  publication-title: Nat Rev Cancer
  doi: 10.1038/nrc725
– volume: 29
  start-page: 1035
  issue: 4
  year: 2009
  ident: 2316_CR71
  publication-title: Mol Cell Biol
  doi: 10.1128/MCB.00336-08
– volume: 127
  start-page: 3039
  issue: Pt 14
  year: 2014
  ident: 2316_CR87
  publication-title: J Cell Sci
– volume: 30
  start-page: 919
  issue: 7
  year: 2017
  ident: 2316_CR17
  publication-title: Mod Pathol
  doi: 10.1038/modpathol.2016.169
– volume: 66
  start-page: 435
  issue: 3
  year: 2019
  ident: 2316_CR19
  publication-title: Endocrine
  doi: 10.1007/s12020-019-02030-8
– volume: 77
  start-page: 112
  issue: 2
  year: 1998
  ident: 2316_CR82
  publication-title: J Surg Res
  doi: 10.1006/jsre.1998.5369
– volume: 1692
  start-page: 103
  issue: 2–3
  year: 2004
  ident: 2316_CR76
  publication-title: Biochim Biophys Acta
  doi: 10.1016/j.bbamcr.2004.04.007
– volume: 12
  start-page: 130
  issue: 1
  year: 2021
  ident: 2316_CR65
  publication-title: Cell Death Dis
  doi: 10.1038/s41419-021-03425-0
– volume: 19
  start-page: 259
  issue: 2
  year: 2010
  ident: 2316_CR83
  publication-title: Dev Cell
  doi: 10.1016/j.devcel.2010.07.015
– volume: 8
  start-page: 109
  issue: 1
  year: 1997
  ident: 2316_CR84
  publication-title: Mol Biol Cell
  doi: 10.1091/mbc.8.1.109
– volume: 49
  start-page: 702
  issue: 7
  year: 2013
  ident: 2316_CR1
  publication-title: Oral Oncol
  doi: 10.1016/j.oraloncology.2013.03.440
– volume: 343
  start-page: 80
  issue: 6166
  year: 2014
  ident: 2316_CR21
  publication-title: Science
  doi: 10.1126/science.1246981
– volume: 2
  start-page: 211
  issue: 5
  year: 2011
  ident: 2316_CR61
  publication-title: Transcription
  doi: 10.4161/trns.2.5.16904
– volume: 133
  start-page: 704
  issue: 4
  year: 2008
  ident: 2316_CR8
  publication-title: Cell
  doi: 10.1016/j.cell.2008.03.027
– volume: 111
  start-page: 1285
  issue: 7
  year: 2001
  ident: 2316_CR48
  publication-title: Laryngoscope
  doi: 10.1097/00005537-200107000-00027
– volume: 421
  start-page: 283
  issue: 2
  year: 2009
  ident: 2316_CR63
  publication-title: Biochem J
  doi: 10.1042/BJ20090061
– volume: 8
  start-page: e76773
  issue: 10
  year: 2013
  ident: 2316_CR14
  publication-title: PLoS One
  doi: 10.1371/journal.pone.0076773
– volume: 13
  start-page: 2498
  issue: 11
  year: 2003
  ident: 2316_CR29
  publication-title: Genome Res
  doi: 10.1101/gr.1239303
– volume: 110
  start-page: 19372
  issue: 48
  year: 2013
  ident: 2316_CR77
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.1307405110
SSID ssj0061919
Score 2.3851714
Snippet Background Anaplastic Thyroid Cancer (ATC) is an undifferentiated and aggressive tumor that often originates from well-Differentiated Thyroid Carcinoma (DTC)...
Anaplastic Thyroid Cancer (ATC) is an undifferentiated and aggressive tumor that often originates from well-Differentiated Thyroid Carcinoma (DTC) through a...
Background Anaplastic Thyroid Cancer (ATC) is an undifferentiated and aggressive tumor that often originates from well-Differentiated Thyroid Carcinoma (DTC)...
Abstract Background Anaplastic Thyroid Cancer (ATC) is an undifferentiated and aggressive tumor that often originates from well-Differentiated Thyroid...
SourceID doaj
pubmedcentral
proquest
gale
pubmed
crossref
springer
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage 108
SubjectTerms Analysis
Anaplastic thyroid cancer
Antibodies
Apoptosis
Biomedical and Life Sciences
Biomedicine
Cancer Research
Cell cycle
Cell death
Cell division
Chromatin
Cytoskeleton dynamics
Embryonic development
Epithelial-Mesenchymal Transition - genetics
Epithelial-to-Mesenchymal Transition
Experiments
Female
Flow cytometry
Gene expression
Genes
Growth factors
Humans
Immunology
Mitosis
Motility
Oncology
OVOL2
Pharmaceutical industry
Plasmids
Pregnancy
Prognosis
rho GTP-Binding Proteins - genetics
RNA
Scientific equipment and supplies industry
Stem cells
Thyroid cancer
Thyroid Carcinoma, Anaplastic - genetics
Thyroid Neoplasms - genetics
Thyroid Neoplasms - pathology
Transcription Factors - genetics
Wound healing
SummonAdditionalLinks – databaseName: ProQuest Central
  dbid: BENPR
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9MwELdGJyFeEN9kDDASEg8QLbEdx3lAqJs2KsTaaerQ3iw7drZKkHRt98B_z52bdGSIvcYXJee7-9354-4IeQ-4WJqCOdxeYrGoMhfbxLo4tVViueEJM7jfcTyWozPx7Tw73yLjLhcGr1V2mBiA2jUl7pHvMQmxBixnVPplfhVj1yg8Xe1aaJi2tYL7HEqM3SPbAMlZMiDb-4fjk9MOm2G1EFp9gM-UMUb6XRqNknvLFA8JY7zdjjXRZMx6ripU9P8Xt_9yXLcvVd46WQ0O6-gRedhGmnS4Vo3HZMvXT8j94_Ys_SmpJj8m3xnFNMnZYklPRxP6dXoCTo3inQ6Daep01VDs3YFtJOgvsP3lbElN7ai5CMv0FilpU9FhbeYQiMO36PTy96KZOXqACrV4Rs6ODqcHo7jtuhCXYIur2HmVgXrlTkkAIJtVLHeZTZyXrqycK5m0quR5VbikMML4kiU2zZwswPJBshV_TgZ1U_uXhApRcJ7yylslRe6l4sIr62wuZZFaYyKSdhOsy7YkObL0U4eliZJ6LRQNQtFBKJpF5OPmnfm6IMed1Psotw0lFtMOD5rFhW5tU6ssF8qxzDIukCGlrDCAdga8txWFj8hblLpeZ6ZuIEEPgWeOx5AyIh8CBYICMFCaNrcBpgHLa_Uod3uUYMxlf7jTLN2CyVLfqH5E3m2G8U28IFf75hpphMBwPeERebFWxA3THEL6nIsiInlPRXuz0h-pZ5eh1Lgqshx-LCKfOmW--a3_z_rO3Vy8Ig9YMDMes2yXDFaLa_8aQruVfdPa6x8DPUiR
  priority: 102
  providerName: ProQuest
– databaseName: Scholars Portal Journals: Open Access
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrR3LbtQw0KqKhLgg3qQUMBISBwgktuM4B4SWirJClEVoF_Vm2bHTrlSSkt1K9O-Z8SaBlMKJazxW4nk78yLkKejF0hTM4e8lFosqc7FNrItTWyWWG54wg_87Dj7J6UJ8OMwOt0g_7qhD4OrSqx3Ok1q0Jy9_fD9_AwL_Ogi8kq9WKYb3YsxLx25mMgaVfCXEizCVTwxRBbgrpEVfOHPpvpFxCj38_9TUv5mqi2mUF2KpwUTt3yDXO9-STjbMcJNs-foWuXrQRc9vk2r2dfaRUSyMXLYr-mU6o-_nn8GMUcziMFiYTtcNxWkdODiCfgNpXy1X1NSOmqNwMe90I20qOqnNKbje8C46Pz5vm6Wje8hC7R2y2H8335vG3ZyFuATpW8fOqwwYKndKgsqxWcVyl9nEeenKyrmSSatKnleFSwojjC9ZYtPMyQJkHWhZ8btku25qf59QIQrOU155q6TIvVRceGWdzaUsUmtMRNIewbrsmpDjkU50uIwoqTdE0UAUHYiiWUSeD3tONy04_gn9Fuk2QGL77PCgaY90J41aZblQjmWWcYEHUsoKA_rNgL22ovAReYxU15ta1EEJ6AmcmWPgUUbkWYBAxoQDlKarZgA0YEOtEeTuCBLEtxwv95yle-7XTIJjDXd3lUbkybCMOzElrvbNGcIIgQ56wiNyb8OIw6E5OPE5F0VE8hGLjrAyXqmXx6G5uCqyHD4sIi96Zv71WX_H-s7_wPoDco0FYeQxy3bJ9ro98w_B5VvbR0GOfwLtmk_N
  priority: 102
  providerName: Scholars Portal
– databaseName: Springer Nature OA Free Journals
  dbid: C6C
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlV3db9QwDI_QkBAvaHyXDQgSEg9Q0ear6eNxYpwQ4xC6ob1FSZOyk6CdrrcH_nvstD3W8SHx2jhqHftnO3XsEPIc7GJlS-bx9xJLRS196jLn09zVmeOWZ8zi_47jj2pxIt6fytOhTQ7WwlzO3-dave5yTN2leOYcO5WpFMztdQkPUZvnaj5aXdgH5OVYFPPHeRPHE_vz_26FL7mhq0ckr-RJo_s52ie3hriRznpB3ybXQnOH3DgeMuN3Sb38svzAKBY9rjcd_bxY0nerT-CiKJ7QsFh0TrctxZs48FII-h2Q3K07ahtP7de46R7sHm1rOmvsOYTV8C66OvuxadeezlE9NvfIydHb1XyRDncopBUga5v6oCUoS-G1AnPiZM0KL13mg_JV7X3FlNMVL-rSZ6UVNlQsc7n0qgQcg5xqfp_sNW0THhIqRMl5zuvgtBJFUJqLoJ13hVJl7qxNSD4usKmGBuPI0jcTNxpamV4oBoRiolAMS8jL3Zzzvr3GP6nfoNx2lNgaOz4AjTED0oyWhdCeSce4QIa0dsKC7bLgi50oQ0KeotRNX2e6A7iZAc8ck4oqIS8iBUIcGKjsUKkAy4DNsiaUhxNKgGY1HR41ywymoTNMQdAM-3KdJ-TZbhhn4nG3JrQXSCMEBt8ZT8iDXhF3THMI0AsuyoQUExWdrMp0pFmfxcbhupQFfFhCXo3K_Ouz_r7qj_6P_IDcZBF2PGXykOxtNxfhMQRuW_ckIvYn4A44yg
  priority: 102
  providerName: Springer Nature
Title OVOL2 impairs RHO GTPase signaling to restrain mitosis and aggressiveness of Anaplastic Thyroid Cancer
URI https://link.springer.com/article/10.1186/s13046-022-02316-2
https://www.ncbi.nlm.nih.gov/pubmed/35337349
https://www.proquest.com/docview/2651982581
https://www.proquest.com/docview/2644001903
https://pubmed.ncbi.nlm.nih.gov/PMC8957195
https://doaj.org/article/85748d25b2344aec88b4a003a801b49e
Volume 41
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3db9MwELdgSIgXxPeyjWIkJB4gWmI7jv3YVhsVoutUdajixbJjh1WCdGq7B_577pK0LEPACy-REl8U--5357v4fCbkDdjFwmrm8fcSi0WZ-dglzsepKxPHLU-Yxf8d4zM5uhAf59n8xlFfmBPWlAduGHesslwozzLHuBA2FEo5YQGKFkyrEzqg9U10sg2mGhsMUUGqt1tklDxep7gAGGPmOtY7kzHrTEN1tf7fbfKNSel2wuStVdN6Mjp9RB62XiTtN71_TO6E6gm5P27XyZ-ScvJ58olR3AK5WK3pdDShH2bnMGFRzNewuAWdbpYUz-XAIyLod9Dr9WJNbeWp_VqH4K0VpMuS9it7BU42fIvOLn-slgtPhwiW1TNycXoyG47i9kSFuAA928Q-qAygk3slwbi4rGS5z1zig_RF6X3BpFMFz0vtE22R2yxxaealBq0GqZX8OdmrllXYJ1QIzXnKy-CUFHmQiougnHe5lDp11kYk3TLYFG25cRzSN1OHHUqaRigGhGJqoRgWkXe7d66aYht_pR6g3HaUWCi7fgDwMS18zL_gE5FXKHXT7Drdqbvpw5g5LjHKiLytKVDhYQCFbfctABuwdFaH8qhDCYpadJu3yDKtoVgbJsGFhihdpRF5vWvGNzH5rQrLa6QRAl3xhEfkRQPE3aA5uOs5FzoieQeiHa50W6rFZV1GXOksh45F5P0WzL-69WeuH_wPrh-SB6xWRh6z7IjsbVbX4SU4dxvXI3fzed4j9wYnZ-dTuBvKYa_WbbiOhYLrdPDlJ9D5TR4
linkProvider Directory of Open Access Journals
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtR1db9Mw0BpDAl4Q3wQGMxKIB4iW2I7jPCBUBqNj7YZQh_pm7DjZKkFSmk5of4rfyF0-OjLE3vZaX9Lct8_nuyPkOdjF1CTM4fES80UeOd8G1vmhzQPLDQ-YwfOO8b4cHopP02i6Rn53tTB4rbKzibWhdmWKZ-RbTMJeA8IZFb6d__RxahRmV7sRGo1Y7GWnvyBkq97svgf-vmBs58Nke-i3UwX8FGRt6btMRUC-2CkJCmajnMUusoHLpEtz51ImrUp5nCcuSIwwWcoCG0ZOQnAO1sPkHN57hVwVmGIE_YmnqwAPYpF6kAh4ZOljHNEV6Si5VYWYgvTx7jx2XJM-6znCel7Av17hL7d4_srmubxt7Q53bpGb7T6WDhrBu03WsuIOuTZuM_V3SX7w9WDEKBZhzhYV_TI8oB8nn8FlUrwxYrAIni5LipNBcEgF_QGWpZpV1BSOmqP6EKC1w7TM6aAwc9jmw3_RyfHpopw5uo3iurhHDi-F-vfJelEW2UNChUg4D3meWSVFnEnFRaass7GUSWiN8UjYEVinbcNzROm7rgMfJXXDFA1M0TVTNPPIq9Uz86bdx4XQ75BvK0hs1V3_UC6OdKv5WkWxUI5FlnGBCCllhQFbamBvYEWSeWQTua6buteVwdEDwJljklN65GUNgSYHEEhNWzkBZMDmXT3IjR4kmIq0v9xJlm5NVaXPFMsjz1bL-CRevyuy8gRhhMBgIOAeedAI4gppDgFDzEXikbgnoj2q9FeK2XHdyFwlUQwf5pHXnTCffdb_qf7oYiw2yfXhZDzSo939vcfkBqtVjvss2iDry8VJ9gQ2kUv7tNZcSr5dtqn4A0CZgRU
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwlR3LbtQw0EKtVHFBvEkp1EhIHCBqYjuOfQyFZVnabgVb1Jtlx0m7EiSr3e2Bv2cmj6UpD4lrPFYynnfmYUJegl7MrWYefy-xUJSJD13kfBi7MnLc8ohZ_N9xfCLHZ2Jynpxf6-Jvqt37lGTb04BTmqr1wcKXrYgrebCKMaEXYiU6zi-TISjhbZVoDeHXdpZNvkx6bQzxQaz7Zpk_7hwYpGZu_-_a-Zp5ulk6eSN_2pil0V1yp_MnadYywD1yq6juk53jLmP-gJTTr9MjRrEZcr5c0c_jKf0wOwXTRbFyw2IzOl3XFG_owMsi6HeQ8NV8RW3lqb1ogvFOH9K6pFllF-Buw7vo7PLHsp57eohss3xIzkbvZ4fjsLtbIcxB4tahL1QCTJR6JUHNuKRkqU9c5Avp89L7nEmncp6W2kfaClvkLHJx4qUG-Qb6lfwR2arqqnhCqBCa85iXhVNSpIVUXBTKeZdKqWNnbUDi_oBN3g0eR5S-mSYAUdK0RDFAFNMQxbCAvN7sWbRjN_4J_RbptoHEkdnNg3p5YToJNCpJhfIscYwLREgpJyzoNAs22gldBGQfqW7a_tON4JsMcOaYbJQBedVAoOgDArntOhjgGHCI1gBybwAJIpsPl3vOMp3KWBkmwZmGeF3FAXmxWcadWAZXFfUVwgiBTnnEA_K4ZcQN0hwc95QLHZB0wKKDUxmuVPPLZqC40kkKHxaQNz0z__qsv5_67v-B75Od03cjc_Tx5NNTcps1EshDluyRrfXyqngGvt3aPe_E9yfgnEV3
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=OVOL2+impairs+RHO+GTPase+signaling+to+restrain+mitosis+and+aggressiveness+of+Anaplastic+Thyroid+Cancer&rft.jtitle=Journal+of+experimental+%26+clinical+cancer+research&rft.au=Mila+Gugnoni&rft.au=Gloria+Manzotti&rft.au=Emanuele+Vitale&rft.au=Elisabetta+Sauta&rft.date=2022-03-25&rft.pub=BMC&rft.eissn=1756-9966&rft.volume=41&rft.issue=1&rft.spage=1&rft.epage=17&rft_id=info:doi/10.1186%2Fs13046-022-02316-2&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_85748d25b2344aec88b4a003a801b49e
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1756-9966&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1756-9966&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1756-9966&client=summon